Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents
Quintero, Jesús. (Hospital Universitari Vall d'Hebron)
Juampérez, Javier (Hospital Universitari Vall d'Hebron)
Julio, Ecaterina (Hospital Universitari Vall d'Hebron)
Cabello, Vanessa (Hospital Universitari Vall d'Hebron)
Mercadal-Hally, Maria (Hospital Universitari Vall d'Hebron)
Soler-Palacín, Pere (Hospital Universitari Vall d'Hebron)
Segarra, Óscar. (Hospital Universitari Vall d'Hebron)
Rodrigo Gonzalo de Líria, Carlos (Hospital Universitari Vall d'Hebron)
Universitat Autònoma de Barcelona

Títol variant:	Combinación de ledipasvir/sofosbuvir como tratamiento de la infección crónica por hepatitis C
Data:	2019
Resum:	Introduction: Hepatitis C virus infection is world health problem. The aim of this study was to assess the safety and efficacy of ledipasvir/sofosbuvir combination in chronic Hepatitis C Virus (HCV) genotype 1 and 4 infection in paediatric patients. Methods: Eligible patients to be treated with ledipasvir/sofosbuvir were patients from 6 to 18 years old with a chronic HCV genotype 1 or 4 infection. The duration and doses of antiviral drugs were changed depending on patient age, fibrosis stage, and PEGylated interferon + ribavirin experience status. The primary efficacy endpoint was the percentage of patients with a sustained virological response 12 weeks post-treatment. Results: A total of nine patients (7 males) with a median age of 14. 8 years (8. 48-17. 91) were treated with ledipasvir/sofosbuvir combination. Five patients received previous treatment with PEGylated interferon + ribavirin during a median of 8. 5 months (3-12 months). Eight patients had some degree of fibrosis (1 patient presented with F1, three patients F2, 2 patients F3, and 2 patients F4). The median pre-treatment viral load was 6. 2 Log [5. 9-6. 8] with the HCV RNA becoming negative six weeks after starting the treatment in 100% of the patients. All patients maintained a sustained viral response at 12 weeks. Three patients (33. 3%) had some type of adverse effect (2 headache and one oral thrush). The median post-treatment follow-up was 24 weeks (12-104). Conclusions: Treatment with ledipasvir/sofosbuvir in paediatric patients with chronic HCV infection genotype 1 and 4 is safe and effective with SVR12 and similar to those reported in adults.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Castellà
Document:	Article ; recerca ; Versió publicada
Publicat a:	Anales de pediatría, Vol. 90 Núm. 3 (marzo 2019) , p. 141-147, ISSN 1695-9531

DOI: 10.1016/j.anpedi.2018.07.007
PMID: 30126773

7 p, 2.9 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats